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It has long been known that myeloid derived suppressor
cells (MDSCs) inhibit the anti-tumor immune response.
And recently a relationship between MDSC levels and
patient outcomes to cancer immunotherapy was discov-
ered. Studies conducted at the Memorial Sloan Kettering
Cancer Center in New York showed that patients with
reduced levels of circulating MDSCs were more likely to
respond favorably to Ipilimumab, an immunotherapy
approved for the treatment of melanoma. This raises the
exciting prospect that baseline levels of MDSCs may help
drug developers and physicians identify or select those
patients who are most likely to benefit from immune-based
cancer treatments. However the development of a robust
and commercially available MDSC biomarker assay pre-
sents many challenges, from sample handling and logistics
to an objective and reproducible definition of this elusive
cell type. Here we present data from our MDSC assay
development program and discuss the merits of applying
this assay to biomarker studies as part of the clinical devel-
opment of novel cancer therapies.
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